Clearside Biomedical Stock Forecast, Price & News

-0.07 (-1.07 %)
(As of 09/16/2021 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume346,694 shs
Average Volume1.49 million shs
Market Capitalization$386.62 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive CLSD News and Ratings via Email

Sign-up to receive the latest news and ratings for Clearside Biomedical and its competitors with MarketBeat's FREE daily newsletter.

Clearside Biomedical logo

About Clearside Biomedical

Clearside Biomedical, Inc. is a biopharmaceutical company, which engages in the development of drug therapies to treat blinding diseases of the eye. Its pipeline includes Suprachoroidal CLS-TA, Suprachoroidal, Suprachoroidal CLS-TA, and gene therapy. The company was founded by Samir Kumar Patel, Vladimir Zarnitsyn, Mark Prausnitz, Daniel H. White, and Henry F. Edelhauser in May 2011 and is headquartered in Alpharetta, GA.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.95 out of 5 stars

Medical Sector

618th out of 1,352 stocks

Pharmaceutical Preparations Industry

300th out of 665 stocks

Analyst Opinion: 3.4Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Clearside Biomedical (NASDAQ:CLSD) Frequently Asked Questions

Is Clearside Biomedical a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Clearside Biomedical in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Clearside Biomedical stock.
View analyst ratings for Clearside Biomedical
or view top-rated stocks.

What stocks does MarketBeat like better than Clearside Biomedical?

Wall Street analysts have given Clearside Biomedical a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Clearside Biomedical wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Clearside Biomedical?

Clearside Biomedical saw a decline in short interest in the month of August. As of August 31st, there was short interest totaling 1,490,000 shares, a decline of 32.6% from the August 15th total of 2,210,000 shares. Based on an average trading volume of 3,190,000 shares, the days-to-cover ratio is currently 0.5 days. Currently, 3.2% of the shares of the stock are sold short.
View Clearside Biomedical's Short Interest

When is Clearside Biomedical's next earnings date?

Clearside Biomedical is scheduled to release its next quarterly earnings announcement on Tuesday, November 9th 2021.
View our earnings forecast for Clearside Biomedical

How were Clearside Biomedical's earnings last quarter?

Clearside Biomedical, Inc. (NASDAQ:CLSD) posted its quarterly earnings results on Monday, August, 9th. The company reported ($0.11) EPS for the quarter, beating analysts' consensus estimates of ($0.13) by $0.02. The company had revenue of $0.78 million for the quarter, compared to the consensus estimate of $0.74 million. Clearside Biomedical had a negative trailing twelve-month return on equity of 172.83% and a negative net margin of 540.08%.
View Clearside Biomedical's earnings history

How has Clearside Biomedical's stock been impacted by Coronavirus (COVID-19)?

Clearside Biomedical's stock was trading at $2.59 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CLSD shares have increased by 151.0% and is now trading at $6.50.
View which stocks have been most impacted by COVID-19

What price target have analysts set for CLSD?

5 Wall Street analysts have issued 1-year target prices for Clearside Biomedical's stock. Their forecasts range from $9.00 to $18.00. On average, they expect Clearside Biomedical's share price to reach $13.00 in the next twelve months. This suggests a possible upside of 100.0% from the stock's current price.
View analysts' price targets for Clearside Biomedical
or view top-rated stocks among Wall Street analysts.

Who are Clearside Biomedical's key executives?

Clearside Biomedical's management team includes the following people:

Who are some of Clearside Biomedical's key competitors?

What other stocks do shareholders of Clearside Biomedical own?

When did Clearside Biomedical IPO?

(CLSD) raised $50 million in an initial public offering on Thursday, June 2nd 2016. The company issued 7,200,000 shares at $7.00 per share. Cowen and Company and Stifel served as the underwriters for the IPO and Needham & Company, Wedbush PacGrow was co-manager.

What is Clearside Biomedical's stock symbol?

Clearside Biomedical trades on the NASDAQ under the ticker symbol "CLSD."

Who are Clearside Biomedical's major shareholders?

Clearside Biomedical's stock is owned by a number of institutional and retail investors. Top institutional investors include Carmignac Gestion (5.94%), Vanguard Group Inc. (3.66%), Acuta Capital Partners LLC (2.21%), BlackRock Inc. (1.34%), Geode Capital Management LLC (0.74%) and Bridgeway Capital Management LLC (0.53%). Company insiders that own Clearside Biomedical stock include Bradford T Whitmore, Bradford T Whitmore, Charles A Deignan, Clay Thorp, George M Lasezkay, George M Lasezkay, Nancy J Hutson, Richard T Burke and William D Humphries.
View institutional ownership trends for Clearside Biomedical

Which major investors are selling Clearside Biomedical stock?

CLSD stock was sold by a variety of institutional investors in the last quarter, including AJU IB Investment Co. Ltd., Renaissance Technologies LLC, Acuta Capital Partners LLC, Carmignac Gestion, Marshall Wace LLP, Marshall Wace LLP, BlackRock Inc., and Morgan Stanley. Company insiders that have sold Clearside Biomedical company stock in the last year include Bradford T Whitmore, Charles A Deignan, Clay Thorp, George M Lasezkay, and Richard T Burke.
View insider buying and selling activity for Clearside Biomedical
or view top insider-selling stocks.

Which major investors are buying Clearside Biomedical stock?

CLSD stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc., EAM Investors LLC, State Street Corp, Geode Capital Management LLC, Ameritas Investment Company LLC, Bridgeway Capital Management LLC, Caxton Associates LP, and Wolverine Trading LLC. Company insiders that have bought Clearside Biomedical stock in the last two years include Bradford T Whitmore, Charles A Deignan, George M Lasezkay, Nancy J Hutson, and William D Humphries.
View insider buying and selling activity for Clearside Biomedical
or or view top insider-buying stocks.

How do I buy shares of Clearside Biomedical?

Shares of CLSD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Clearside Biomedical's stock price today?

One share of CLSD stock can currently be purchased for approximately $6.50.

How much money does Clearside Biomedical make?

Clearside Biomedical has a market capitalization of $386.62 million and generates $7.89 million in revenue each year. The company earns $-18,210,000.00 in net income (profit) each year or ($0.39) on an earnings per share basis.

How many employees does Clearside Biomedical have?

Clearside Biomedical employs 33 workers across the globe.

What is Clearside Biomedical's official website?

The official website for Clearside Biomedical is

Where are Clearside Biomedical's headquarters?

Clearside Biomedical is headquartered at 900 NORTH POINT PARKWAY SUITE 200, ALPHARETTA GA, 30005.

How can I contact Clearside Biomedical?

Clearside Biomedical's mailing address is 900 NORTH POINT PARKWAY SUITE 200, ALPHARETTA GA, 30005. The company can be reached via phone at (678) 270-3631 or via email at [email protected]

This page was last updated on 9/16/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.